/PRNewswire/ --Â Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that , President and Chief Executive...
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $10.8 million in its second quarter.
/PRNewswire/ --Â Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its...
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on , the independent Compensation...
Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...
New York, New York--(Newsfile Corp. - June 26, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc.("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised...
/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will be added to the Russell...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact at   or 888-476-6529,...
Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. ("Curis" or the "Company") (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com...
